Generic: Insulin Glulisine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.4M | 6,116 | 1,561 | $27.78 |
| 2020 | $4.5M | 4,628 | 1,146 | $27.78 |
| 2021 | $3.8M | 3,667 | 931 | $28.13 |
| 2022 | $3.0M | 2,762 | 747 | $28.42 |
| 2023 | $2.8M | 2,457 | 676 | $28.62 |
| State | Total Drug Cost | Claims | Prescribers | Beneficiaries |
|---|---|---|---|---|
| California | $271.0K | 278 | 90 | 82 |
| Michigan | $256.7K | 192 | 56 | 53 |
| New Jersey | $208.6K | 147 | 43 | 38 |
| Ohio | $185.4K | 123 | 42 | 35 |
| Pennsylvania | $184.2K | 210 | 55 | 53 |
| Georgia | $118.5K | 103 | 28 | 24 |
| New York | $117.1K | 125 | 43 | 39 |
| Texas | $102.6K | 106 | 37 | 33 |
| Florida | $102.5K | 85 | 37 | 35 |
| Connecticut | $97.3K | 53 | 16 | 16 |
| North Carolina | $91.3K | 82 | 18 | 18 |
| Massachusetts | $84.7K | 52 | 16 | 16 |
| Indiana | $82.8K | 55 | 14 | 15 |
| Kentucky | $62.8K | 66 | 21 | 17 |
| Illinois | $60.2K | 58 | 19 | 17 |
| Missouri | $53.7K | 53 | 18 | 16 |
| Maine | $51.7K | 35 | 9 | N/A |
| Arizona | $49.2K | 41 | 13 | 12 |
| South Carolina | $42.2K | 23 | 6 | N/A |
| Virginia | $34.7K | 38 | 12 | 12 |
| Puerto Rico | $33.3K | 75 | 13 | 11 |
| Maryland | $29.9K | 37 | 7 | N/A |
| Utah | $29.8K | 33 | 5 | N/A |
| Kansas | $26.5K | 14 | 4 | N/A |
| Mississippi | $26.0K | 24 | 11 | N/A |
| Nebraska | $25.4K | 17 | 2 | N/A |
| Washington | $25.0K | 25 | 8 | N/A |
| Nevada | $24.9K | 11 | 4 | N/A |
| Louisiana | $24.9K | 43 | 10 | 12 |
| Colorado | $24.4K | 13 | 4 | N/A |
| Oregon | $24.4K | 23 | 6 | N/A |
| Minnesota | $22.9K | 38 | 8 | N/A |
| Alabama | $21.9K | 17 | 6 | N/A |
| Delaware | $18.6K | 11 | 4 | N/A |
| Idaho | $16.4K | 24 | 9 | N/A |
| Arkansas | $16.2K | 14 | 3 | N/A |
| Oklahoma | $15.8K | 20 | 6 | N/A |
| Tennessee | $15.5K | 14 | 9 | N/A |
| Wisconsin | $14.0K | 12 | 4 | N/A |
| Iowa | $9.7K | 13 | 5 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.